486422-11-1

Basic information

• Product Name: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid
• Synonyms: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid;4-(4-methyl-piperazinesulfonyl)phenyl boronic acid;[4-[(4-Methyl-1-piperazinyl)sulfonyl]phenyl]boronic acid;[4-[(4-Methyl-1-piperazinyl)sulfonyl]phenyl]boronic acid（WS204875）
• CAS NO: 486422-11-1
• Molecular Formula: C₁₁H₁₇BN₂O₄S
• Molecular Weight: 284.13968
• Product Categories: Boronate Ester;Boronic Acid;Potassium Trifluoroborate
• Mol File: 486422-11-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid(486422-11-1)
• EPA Substance Registry System: 4-(4-Methylpiperazin-1-ylsulfonyl)phenylboronic acid(486422-11-1)

Safety Data

• Hazardous Substances Data: 486422-11-1(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 837-12-7 1-((4-bromophenyl)sulfonyl)-4-methylpiperazine 

Downstream Products

• 1246203-90-6 2-(difluoromethyl)-4-methoxy-1-[4-{4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl}-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole 
• 1580453-34-4 6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine 
• 1432450-58-2 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)quinazolin-4-amine 
• 486424-20-8 AZD₂₈₅₈ 
• 714237-17-9 3-amino-N-(4-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 714237-16-8 3-amino-N-(2-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 714218-77-6 3-amino-N-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 714218-76-5 3-amino-N-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 714237-32-8 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride 
• 486423-57-8 4-amino-4'-[(4-methylpiperazin-1-yl)sulfonyl]-N-pyridin-3-yl-1,1'-biphenyl-3-carboxamide 

Relevant articles and documents

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimers Disease: Design, synthesis, and characterization of pyrazines

Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3β localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimers disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and bloo-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimers disease.

NEW ANTI-MALARIAL AGENTS

The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharm

NOBEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3

The present invention relates to new compounds, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, such as pr

NOBEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3

The present invention relates to new compounds of formula (I) wherein Z is N; Y is CONR5, NR5CO, SO2NR5, NR5SO2, CH2NR5, NR5, NR5CONR5